Jump to content

Sinopharm (company): Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎COVID-19 vaccine: Rm self link
Tags: Mobile edit Mobile web edit
Line 70: Line 70:
{{main|BBIBP-CorV}}
{{main|BBIBP-CorV}}


'''BBIBP-CorV''', is one of two [[Inactivated vaccine|inactivated virus]] [[COVID-19 vaccine|COVID-19 vaccines]] developed by [[Sinopharm]]. In late December 2020, it was in [[Phases of clinical research#Phase III|Phase III trials]] in [[Argentina]], [[Bahrain]], [[Egypt]], [[Morocco]], [[Pakistan]], [[Peru]], and the [[United Arab Emirates]] (UAE) with over 60,000 participants.<ref name=":5">{{Cite news|author=Reuters Staff|date=2020-11-19|title=China Sinopharm's coronavirus vaccine taken by about a million people in emergency use|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm-idUSKBN27Z0PY|access-date=2020-12-09}}</ref>
'''BBIBP-CorV''', is one of two [[Inactivated vaccine|inactivated virus]] [[COVID-19 vaccine|COVID-19 vaccines]] developed by Sinopharm. In late December 2020, it was in [[Phases of clinical research#Phase III|Phase III trials]] in [[Argentina]], [[Bahrain]], [[Egypt]], [[Morocco]], [[Pakistan]], [[Peru]], and the [[United Arab Emirates]] (UAE) with over 60,000 participants.<ref name=":5">{{Cite news|author=Reuters Staff|date=2020-11-19|title=China Sinopharm's coronavirus vaccine taken by about a million people in emergency use|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm-idUSKBN27Z0PY|access-date=2020-12-09}}</ref>


On December 9, the UAE announced interim results from Phase III trials showing BBIBP-CorV had a 86% efficacy against COVID-19 infection.<ref>{{Cite web|title=UAE: Ministry of Health announces 86 per cent vaccine efficacy|url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571|access-date=2020-12-13|website=gulfnews.com|language=en}}</ref> In late December, Sinopharm announced that its internal analysis indicated a 79% efficacy.<ref>{{Cite news|last1=Wee|first1=Sui-Lee|last2=Qin|first2=Amy|date=2020-12-30|title=China Approves Covid-19 Vaccine as It Moves to Inoculate Millions|language=en-US|work=The New York Times|url=https://www.nytimes.com/2020/12/30/business/china-vaccine.html|access-date=2021-02-12|issn=0362-4331}}</ref> While mRNA vaccines like the [[Pfizer–BioNTech COVID-19 vaccine]] and [[mRNA-1273]] showed higher efficacy of +90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.<ref name=":62">{{Cite news|date=2020-12-09|title=China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says|language=en|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19|access-date=2020-12-09}}</ref> BBIBP-CorV shares similar technology with [[CoronaVac]] and [[BBV152]], other inactivated virus vaccines for COVID-19 being developed in Phase III trials.<ref>{{cite journal|vauthors=Cohen J|date=December 2020|title=China's vaccine gambit|url=https://science.sciencemag.org/content/370/6522/1263|journal=Science|volume=370|issue=6522|pages=1263–1267|bibcode=2020Sci...370.1263C|doi=10.1126/science.370.6522.1263|pmid=33303601|doi-access=free}}</ref><ref name="bbc._Covi">{{Cite web|date=16 December 2020|title=Covid: What do we know about China's coronavirus vaccines?|url=https://www.bbc.com/news/world-asia-china-55212787|access-date=18 December 2020|vauthors=Tan Y|agency=[[BBC News]]}}</ref>
On December 9, the UAE announced interim results from Phase III trials showing BBIBP-CorV had a 86% efficacy against COVID-19 infection.<ref>{{Cite web|title=UAE: Ministry of Health announces 86 per cent vaccine efficacy|url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571|access-date=2020-12-13|website=gulfnews.com|language=en}}</ref> In late December, Sinopharm announced that its internal analysis indicated a 79% efficacy.<ref>{{Cite news|last1=Wee|first1=Sui-Lee|last2=Qin|first2=Amy|date=2020-12-30|title=China Approves Covid-19 Vaccine as It Moves to Inoculate Millions|language=en-US|work=The New York Times|url=https://www.nytimes.com/2020/12/30/business/china-vaccine.html|access-date=2021-02-12|issn=0362-4331}}</ref> While mRNA vaccines like the [[Pfizer–BioNTech COVID-19 vaccine]] and [[mRNA-1273]] showed higher efficacy of +90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.<ref name=":62">{{Cite news|date=2020-12-09|title=China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says|language=en|work=Bloomberg.com|url=https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19|access-date=2020-12-09}}</ref> BBIBP-CorV shares similar technology with [[CoronaVac]] and [[BBV152]], other inactivated virus vaccines for COVID-19 being developed in Phase III trials.<ref>{{cite journal|vauthors=Cohen J|date=December 2020|title=China's vaccine gambit|url=https://science.sciencemag.org/content/370/6522/1263|journal=Science|volume=370|issue=6522|pages=1263–1267|bibcode=2020Sci...370.1263C|doi=10.1126/science.370.6522.1263|pmid=33303601|doi-access=free}}</ref><ref name="bbc._Covi">{{Cite web|date=16 December 2020|title=Covid: What do we know about China's coronavirus vaccines?|url=https://www.bbc.com/news/world-asia-china-55212787|access-date=18 December 2020|vauthors=Tan Y|agency=[[BBC News]]}}</ref>

Revision as of 03:31, 12 May 2021

"Sinopharm" redirects here. For other uses, see Sinopharm (disambiguation).
China National Pharmaceutical Group
Sinopharm
Company typestate-owned enterprise
FoundedNovember 26, 1998
Headquarters
Beijing
,
China
Area served
China, exported worldwide
Key people
Guo Jianxin (Chairman & Party Committee Secretary)[1][2]
RevenueIncrease CN¥247.110 billion (2014)
Increase CN¥8.758 billion (2014)
Increase CN¥2.705 billion (2014)
Total assetsIncrease CN¥199.192 billion (2014)
Total equityIncrease CN¥31.944 billion (2014)
OwnerChinese central government (100%)
ParentSASAC of the State Council
Subsidiaries
Chinese name
Simplified Chinese中国医药集团总公司
Traditional Chinese中國醫藥集團總公司
Transcriptions
Standard Mandarin
Hanyu PinyinZhōngguó yīyào jítuán zǒng gōngsī
short Chinese name
Simplified Chinese国药集团
Traditional Chinese國藥集團
Transcriptions
Standard Mandarin
Hanyu PinyinGuóyào jítuán
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[3]

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine [zh] (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.).[4] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai) and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[5]

Sinopharm was ranked 205th in 2016 Fortune Global 500 list.[6]

History

China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) was founded on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).

Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[7]

COVID-19 vaccine

Main article: BBIBP-CorV

BBIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. In late December 2020, it was in Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[8]

On December 9, the UAE announced interim results from Phase III trials showing BBIBP-CorV had a 86% efficacy against COVID-19 infection.[9] In late December, Sinopharm announced that its internal analysis indicated a 79% efficacy.[10] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of +90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[11] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19 being developed in Phase III trials.[12][13]

Based on the data provided to WHO, the vaccine shows a 78.1 percent efficacy against symptomatic COVID-19 in phase III trials, (21 cases in vaccinated group vs. 95 cases in placebo group). Real-world test-negative analysis in Bahrain (based on 14 days post 2nd dose) indicated a vaccine effectiveness of 90 percent for adults aged 18-59, and 91 percent for those 60 year old or older [14].

BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[15][16][17] Africa,[18][19][20] South America,[21][22][23] and Europe.[24][25][26] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[27] On March 26, Sinopharm said more than 80 million doses had been administered.[28]


On 7 May 2021, the World Health Organization announced that it would authorize emergency use of the Sinopharm vaccine for COVID-19.[29][30]

See also

References

  1. ^ "中国医药集团总公司郭建新职务变动情况" (in Chinese). SASAC of the State Council. 6 May 2014. Retrieved 22 November 2016.
  2. ^ "管理团队" (in Chinese). Sinopharm. Retrieved 22 November 2016.
  3. ^ "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
  4. ^ "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
  5. ^ "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
  6. ^ http://beta.fortune.com/global500/sinopharm-205
  7. ^ "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
  8. ^ Reuters Staff (2020-11-19). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Retrieved 2020-12-09. {{cite news}}: |author= has generic name (help)
  9. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. Retrieved 2020-12-13.
  10. ^ Wee, Sui-Lee; Qin, Amy (2020-12-30). "China Approves Covid-19 Vaccine as It Moves to Inoculate Millions". The New York Times. ISSN 0362-4331. Retrieved 2021-02-12.
  11. ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
  12. ^ Cohen J (December 2020). "China's vaccine gambit". Science. 370 (6522): 1263–1267. Bibcode:2020Sci...370.1263C. doi:10.1126/science.370.6522.1263. PMID 33303601.
  13. ^ Tan Y (16 December 2020). "Covid: What do we know about China's coronavirus vaccines?". BBC News. Retrieved 18 December 2020.
  14. ^ Kirsten, Vannice; Marti, Melanie (2021-04-29). "Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine" (PDF). WHO.
  15. ^ Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.{{cite news}}: CS1 maint: url-status (link)
  16. ^ Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
  17. ^ Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
  18. ^ Reuters Staff (2021-01-24). "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. Retrieved 2021-01-24. {{cite news}}: |author= has generic name (help)
  19. ^ Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
  20. ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
  21. ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. Retrieved 2021-03-26.
  22. ^ Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
  23. ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
  24. ^ "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". RadioFreeEurope/RadioLiberty. Retrieved 2021-01-21.
  25. ^ "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
  26. ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
  27. ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
  28. ^ Liu, Roxanne (2021-03-26). "100 million doses of China Sinopharm's COVID-19 vaccines supplied globally". Reuters. Retrieved 2021-03-26.{{cite news}}: CS1 maint: url-status (link)
  29. ^ Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Archived from the original on 7 May 2021. Retrieved 8 May 2021.
  30. ^ "Sinopharm: Chinese Covid vaccine gets WHO emergency approval". BBC News. 7 May 2021. Archived from the original on 7 May 2021. Retrieved 8 May 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sinopharm_(company)&oldid=1022723403"